Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05129124 · ClinicalTrials.gov registry record · NA
Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
A NA study of Astigmatism, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05129124: Completed NA study of Astigmatism, sponsored by Bausch & Lomb Incorporated.
NCT05129124 is a NA study of Astigmatism that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 30 participants, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05129124, a NA study of Astigmatism, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to evaluate the fit characteristics (primary gaze orientation, rotational recovery, and movement) of kalifilcon A daily disposable toric lenses as compared to commercially available Ultra for Astigmatism lenses.
Primary Outcome
Primary gaze orientation is measured in degrees. Measurement Description: Primary gaze is when the patient is looking straight ahead. Orientation refers to how much the contact lens is rotated on the eye. Primary gaze orientation of the contact lens is measured in degrees at the slit-lamp (microscope) using a reticle (protractor). Lens orientation was measured in primary gaze in 5-degree increments. Negative values indicate the contact lens was rotated in the temporal direction. Positive values
Conditions Studied
Interventions
- DEVICE kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
- DEVICE Commercially available Ultra for Astigmatism Contact Lenses
Study Locations (1)
New York
- Bausch and Lomb Site 01 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2022-01-13 |
| Phase | NA |
What the finished NCT05129124 record still lists
NCT05129124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Astigmatism appearing as the primary indexed condition, and to 2 interventions - of which kalifilcon A Daily Disposable Toric LD213001 Contact Lenses is the first listed.
NCT05129124 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05129124 about?
NCT05129124 is a clinical study titled "Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses". The objective is to evaluate the fit characteristics (primary gaze orientation, rotational recovery, and movement) of kalifilcon A daily disposable toric lenses as compared to commercially available Ultra for Astigmatism lenses.
What is the current status of trial NCT05129124?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-11-30. Estimated completion is 2022-01-13.
What conditions does trial NCT05129124 study?
This clinical trial studies the following conditions: Astigmatism.
What interventions are being tested in trial NCT05129124?
The interventions under investigation include: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses (DEVICE), Commercially available Ultra for Astigmatism Contact Lenses (DEVICE).
Who is sponsoring clinical trial NCT05129124?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05129124 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astigmatism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05129124's enrollment target sits among peer trials
30 27th of 31 higher than 4 of 31 other Astigmatism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Astigmatism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery
RECRUITING · NA
-
A Three-Phase Contralateral Comparison of Ray-Tracing Guided LASIK Versus Three Other Refractive Surgery Platforms to Correct Myopia or Myopia With Astigmatism
RECRUITING · NA
-
Contoura With Phorcides Compared to Wavefront Optimized LASIK
RECRUITING · NA
-
Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction
ACTIVE NOT RECRUITING · NA
-
LASIK iDesign vs SMILE
ACTIVE NOT RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI